Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iPSC NK Cells Targeting CLL1 in r/r AML
NCT06027853Phase 1Recruiting
- Sponsor
- Zhejiang University
- Start
- Sep 2023
- Primary completion
- Aug 2026
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CLL1 CAR-NK cells in acute myeloid leukemia (AML), sponsored by Zhejiang University. Primary endpoints: Incidence of Treatment-Emergent Adverse Events at 28 days and Incidence of Dose Limiting Toxicities at 28 days. Started Sep 2023; status: recruiting.
02
Drugs
CLL1 CAR-NK cells
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06027853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06027853.